LAS VEGAS, March 5, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today it has signed a service agreement with Advinus Therapeutics Limited, India, to perform validating preclinical studies for Caprospinol (SP-233), the company’s lead Alzheimer’s drug.
